InsidersTradesSigma
申报总数
公司
▲ 买入（0 笔）
▼ 卖出（9 笔）
内部人交易记录
其他已披露买入
0
已披露卖出
9
尚无足够的、已确定 T+90 期限的买入信号来衡量交易记录。
信号历史
Browse the full record of transactions filed by Hewes L. Becker. Officer active across 2 companies, notably Blueprint Medicines Corp. Aggregated, 20 disclosures have been logged. Split: 0 buy · 9 sells. Total volume traded: €1.4m. Activity tracked since 2 June 2021. The latest transaction was disclosed on 5 January 2026 (Attribution). Regulator: SEC (Form 4). All data is free.
Companies and markets linked to Hewes L. Becker
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
申报20 总计
264,629 股0Common StockSEC:0001193125-26-006723:0
21,353 股Common StockSEC:0001104659-25-069391:0
4,863 股@ US$88.8012.2% 占其流量Common StockSEC:0001415889-25-007407:0
11,000 股0Common StockSEC:0001415889-25-006611:0
2,424 股@ US$104.917.0% 占其流量Common StockSEC:0001415889-24-015734:0
10,573 股@ US$66.2419.3% 占其流量Common StockSEC:0001415889-24-015315:0
3,097 股@ US$90.697.7% 占其流量Common StockSEC:0001415889-24-007562:0
12,500 股0Common StockSEC:0001415889-24-007015:0
1,404 股@ US$52.052.0% 占其流量Common StockSEC:0001415889-23-009402:0
1,466 股@ US$45.721.9% 占其流量Common StockSEC:0001415889-23-004563:0
12,500 股0Common StockSEC:0001415889-23-004265:0
1,220 股@ US$59.762.6% 占其流量Common StockSEC:0001415889-22-006307:0
2,219 股@ US$60.004.6% 占其流量Common StockSEC:0001415889-22-003186:0
1,047 股@ US$56.192.1% 占其流量Common StockSEC:0001415889-22-002734:0
8,750 股0Common StockSEC:0001415889-22-002439:0
729 股@ US$66.241.6% 占其流量Common StockSEC:0001179110-21-011105:0
729 股@ US$66.241.6% 占其流量Common StockSEC:0001179110-21-010209:0
729 股@ US$66.241.6% 占其流量Common StockSEC:0001179110-21-009515:0
8,750 股@ US$66.2418.6% 占其流量Common StockSEC:0001179110-21-008827:0
1,292 股@ US$89.033.6% 占其流量Common StockSEC:0001179110-21-008826:0
20 条申报中的 20 条
About Hewes L. Becker
Hewes L. Becker is a declarant with 20 filings in total. Among the 20 sampled recent filings, they relate to disposals, with EUR 0 of purchases and EUR 1,366,909 of sales between 2021-09-17 and 2026-01-07. The filings concern Blueprint Medicines Corp, where the person is Chief Medical Officer, and Galecto, Inc., where the person is also Chief Medical Officer.
